Equal-Weight ETFs Are the Play for Small-Cap Drug Development. Here's How to Position Now [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Gilead Sciences and Amgen; SPDR S&P Biotech ETF (XBI) uses equal-weight methodology with 155 holdings across smaller companies and returned 77% over the same period, offering higher volatility and asymmetric upside; Direxion Daily S&P Biotech Bull 3X Shares (LABU) amplifies daily returns and gained 338% in the past year but loses 72% over a decade due to volatility decay and is designed for short-term trading only. Biotech ETFs offer three distinct risk-return profiles as drug approvals, obesity and GLP-1 programs, oncology pipelines, and renewed merger activity drive capital back into the sector. The analyst who called NVIDIA in 2010 just named his top 10 AI stocks. Get them here FREE Biotech has reasserted itself over the past year as drug approvals, obesity and GLP-1 programs, oncology pipelines, and renewed merger activity pulled capital back into a sector that spent much of the prior cycle in drawdown. The three ETFs below offer distinct ways to participate: one anchors a p
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences to Release First Quarter 2026 Financial Results on Thursday, May 7, 2026Business Wire
- Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now? [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences: Why I'm Tempted To Sell Ahead Of Q1 Earnings - But Won't [Seeking Alpha]Seeking Alpha
- Arcus halts Gilead-partnered late-stage trial for lung cancer drug [Seeking Alpha]Seeking Alpha
- Citi Raises Gilead (GILD) Price Target Ahead of Q1 Biopharma Preview [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 4/16/26 - Form 4
- 4/16/26 - Form 4
- 4/15/26 - Form 144
- GILD's page on the SEC website